

Food and Drug Administration, HHS

§ 890.3

890.3750	Mechanical table.
890.3760	Powered table.
890.3790	Cane, crutch, and walker tips and pads.
890.3800	Motorized three-wheeled vehicle.
890.3825	Mechanical walker.
890.3850	Mechanical wheelchair.
890.3860	Powered wheelchair.
890.3880	Special grade wheelchair.
890.3890	Stair-climbing wheelchair.
890.3900	Standup wheelchair.
890.3910	Wheelchair accessory.
890.3920	Wheelchair component.
890.3930	Wheelchair elevator.
890.3940	Wheelchair platform scale.

Subpart E [Reserved]

Subpart F—Physical Medicine Therapeutic Devices

890.5050	Daily activity assist device.
890.5100	Immersion hydrobath.
890.5110	Paraffin bath.
890.5125	Nonpowered sitz bath.
890.5150	Powered patient transport.
890.5160	Air-fluidized bed.
890.5170	Powered flotation therapy bed.
890.5180	Manual patient rotation bed.
890.5225	Powered patient rotation bed.
890.5250	Moist steam cabinet.
890.5275	Microwave diathermy.
890.5290	Shortwave diathermy.
890.5300	Ultrasonic diathermy.
890.5350	Exercise component.
890.5360	Measuring exercise equipment.
890.5370	Nonmeasuring exercise equipment.
890.5380	Powered exercise equipment.
890.5410	Powered finger exerciser.
890.5500	Infrared lamp.
890.5525	Iontophoresis device.
890.5575	Powered external limb overload warning device.
890.5650	Powered inflatable tube massager.
890.5660	Therapeutic massager.
890.5700	Cold pack.
890.5710	Hot or cold disposable pack.
890.5720	Water circulating hot or cold pack.
890.5730	Moist heat pack.
890.5740	Powered heating pad.
890.5765	Pressure-applying device.
890.5850	Powered muscle stimulator.
890.5860	Ultrasound and muscle stimulator.
890.5880	Multi-function physical therapy table.
890.5900	Powered traction equipment.
890.5925	Traction accessory.
890.5940	Chilling unit.
890.5950	Powered heating unit.
890.5975	Therapeutic vibrator.

AUTHORITY: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.

SOURCE: 48 FR 53047, Nov. 23, 1983, unless otherwise noted.

EDITORIAL NOTE: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

Subpart A—General Provisions

§ 890.1 Scope.

(a) This part sets forth the classification of physical medicine devices intended for human use that are in commercial distribution.

(b) The identification of a device in a regulation in this part is not a precise description of every device that is, or will be, subject to the regulation. A manufacturer who submits a pre-market notification submission for a device under part 807 may not show merely that the device is accurately described by the section title and identification provisions of a regulation in this part, but shall state why the device is substantially equivalent to other devices, as required by § 807.87.

(c) To avoid duplicative listings, a physical medicine device that has two or more types of uses (e.g., used both as a diagnostic device and as a therapeutic device) is listed only in one subpart.

(d) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.

(e) Guidance documents referenced in this part are available on the Internet at <http://www.fda.gov/cdrh/guidance.html>.

[52 FR 17741, May 11, 1987, as amended at 73 FR 34860, June 19, 2008]

§ 890.3 Effective dates of requirement for premarket approval.

A device included in this part that is classified into class III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the device unless the manufacturer has an approval under section 515 of the act (unless an exemption has been granted under section 520(g)(2) of the act). An approval under section 515 of the act consists of FDA's issuance of an order approving an application of premarket approval (PMA) for the device or declaring completed a product development protocol (PDP) for the device.

(a) Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has

an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later. See section 501(f)(2)(B) of the act. Accordingly, unless an effective date of the requirement for premarket approval is shown in the regulation for a device classified into class III in this part, the device may be commercially distributed without FDA's issuance of an order approving a PMA or declaring completed a PDP for the device. If FDA promulgates a regulation under section 515(b) of the act requiring premarket approval for a device, section 501(f)(1)(A) of the act applies to the device.

(b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. If FDA knows that a device being commercially distributed may be a “new” device as defined in this section because of any new intended use or other reasons, FDA may codify the statutory classification of the device into class III for such new use. Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.

[52 FR 17741, May 11, 1987]

§ 890.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act).

The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of

class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when:

(a) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;

(b) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or

(c) The device is an in vitro device that is intended:

(1) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;

(2) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;

(3) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;